PCN224 Treatment benefit discontinuation : comparison of a partitioned survival analysis and a semi-Markov multi-state model approach using an oncology case study by Cranmer, H. et al.
This is a repository copy of PCN224 Treatment benefit discontinuation : comparison of a 
partitioned survival analysis and a semi-Markov multi-state model approach using an 
oncology case study.




Cranmer, H., Shields, G. and Bullement, A. orcid.org/0000-0001-7091-0972 (2019) 
PCN224 Treatment benefit discontinuation : comparison of a partitioned survival analysis 
and a semi-Markov multi-state model approach using an oncology case study. In: Value in 






Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Treatment Benefit Discontinuation: Comparison of a Partitioned Survival Analysis and a 
Semi-Markov Multi-State Model Approach Using an Oncology Case Study
Cranmer H1, Shields G2, 3, Bullement A.4
1Takeda UK, High Wycombe, UK; 2University of Manchester, Manchester, UK; 3Azurite Research, Sheffield, UK; 4Delta Hat, Nottingham, UK.
Background




• Three scenarios were explored within the PartSA framework: 
– 1) A constant treatment benefit for the duration of the model time horizon
– 2) No treatment benefit beyond the median follow-up period (15-months)
– 3) No treatment benefit beyond the maximum follow-up period (24-months)
• As TX1 is the treatment of interest, scenarios (2) and (3) used TX2 as the reference treatment and reduced 
the survival benefit for TX1 to TX2 after 15- and 24-months, respectively. This is a method commonly 
applied in PartSA when exploring treatment benefit discontinuation. 
• Figure 2 presents the extrapolated overall survival curves for TX1 and TX2 under each of the treatment 
benefit scenarios. 
Results
Incremental costs Incremental QALYs ICER
PartSA
Scenario 1 £78,045 0.23 £342,474
Scenario 2 £72,031 0.09 £803,992
Scenario 3 £72,994 0.11 £653,301
Semi-Markov MSM £78,199 0.19 £416,030
Table 2. Cost-effectiveness results
Abbreviations: ICER, incremental cost-effectiveness ratio; MSM, multi-state model; PartSA, partitioned survival analysis; QALY, quality adjusted life year
Conclusions
• The commonly used PartSA framework often assumes a constant treatment effect across the model time 
horizon. Due to the assumptions underpinning the structure, this treatment effect does not change based 
on the evolving proportion of patients off-treatment or progressed over time. 
• The UK guidance requires exploration into the impact of this assumption on results. However, scenarios 
presented are often arbitrary. For example: there may be no justification with relation to the time point at 
which the treatment effect is assumed to stop or the duration of the treatment effect after treatment 
discontinuation. Furthermore, often the treatment effect of the intervention is explored and not the 
treatment effect of the comparators. 
• Attempting to incorporate some dependency between endpoints (for example: linking the treatment 
benefit to progression or treatment discontinuation) within a PartSA contradicts the underlying PartSA 
structure. If the treatment effect on survival is expected to be related to other outcomes (like progression 
or time on treatment) then this questions the choice of PartSA as the preferred model structure. 
• A more flexible model structure, such as an MSM (in this case study) allows a separate treatment effect to 
be modelled for patients in the pre-progression health state vs. those patients in the progressed disease 
health state. Therefore, the overall survival within the model evolves over time as more patients enter the 
progressed disease health state. 
– This example uses a model structure defined by progression. However, other outcomes like duration 
of treatment may better reflect some pathways. 
• Therefore, in pathways where the treatment effect on survival is likely to evolve over time a more flexible 
model structure should be considered. This study highlights that exploring treatment benefit 
discontinuation scenarios within a PartSA framework may still over estimate long-term survival. 
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• To determine the value of cancer treatments across a patient’s lifetime, the short-term outcomes observed 
in clinical trials often require extrapolation to inform the long-term trends.
– The more immature the trial data, the more uncertain the extrapolation as the extrapolation methods 
have limited information from which to predict outcomes. 
• Many treatments for cancer are associated with a benefit that is expected to extend beyond the clinical trial 
period – either due to the sustained efficacy of treatment or because patients remain on treatment beyond 
the clinical trial cut-off. However, the treatment benefit is not expected to extend indefinitely – particularly 
when the model time horizon far exceeds the duration of treatment. 
• The partitioned survival analysis (PartSA) three-state model was identified as the most common model 
structure in oncology (see also #PCN106).1 Applying standard techniques within a PartSA structure 
assumes that the treatment effect over time is the same regardless of a patient occupying the pre-
progression or progressed disease health state. 
– Therefore, the survival rate over time does not reflect the increasing proportion of patients in the 
progressed health state. 
• However, a more flexible model structure, such as a multi-state model (MSM) allows for the treatment effect 
to differ for patients in each health state – perhaps reflecting a more realistic pathway.
• Within a PartSA, the guidance from the UK health technology appraisal (HTA) body is to explore the impact 
of: (1) no treatment benefit in the extrapolation period, (2) the same benefit as during the trial and (3) a 
diminishing treatment benefit.1 These scenarios are often not supported by clinical rationale. 
• In line with this guidance, we consider comparing three scenarios exploring treatment benefit reduction in a 
PartSA framework. We then compare these results with unadjusted results from a semi-Markov MSM. 
Figure 3. Proportion of patients in the progressed health state over time
• To compare the clinical and economic outcomes associated with three scenarios around the treatment 
benefit in a PartSA structure and to compare this with the outcomes of a semi-Markov MSM structure. 
Objective































Abbreviations: MSM, multi-state model; PartSA, partitioned survival analysis
• Table 1 and Table 2 present the clinical and economic outcomes predicted from each of the scenarios and 
model structures. 
• The PartSA is associated with ICERs of £342,474, £803,992 and £653,301 for each of the scenarios, 
respectively. Whereas, the MSM is associated with an ICER of £416,030. 
Pre-progression life years Progressed disease life years Total life years 
PartSA
Scenario 1 2.44 1.97 4.41
Scenario 2 2.44 1.74 4.18
Scenario 3 2.44 1.78 4.22
Semi-Markov MSM 2.41 1.07 3.48
Table 1. Clinical outcomes associated with TX1
Abbreviations: MSM, multi-state model; PartSA, partitioned survival analysis
Abbreviations: MSM, multi-state model; PartSA, partitioned survival analysis
• Figure 3 presents the proportion of patients in the progressed disease health state over time for each of the 
scenarios within the PartSA and the semi-Markov model structure. 
• Although curtailing the treatment benefit in scenario (2) and (3) reduces the proportion of patients in the 
progressed disease health state over time, this still remains noticeably higher than predicted in the MSM 
structure. Therefore, the PartSA may still be over-estimating long-term survival. 
– Note: this may be because these methods only reduce the survival rate for TX1 to that of TX2. Whereas, 
it is likely that the treatment benefit of TX2 would also decline over time. However, within a PartSA 
framework there is limited ability to account for this without inclusion of external data. 
• In the PartSA model by ~15-years all patients have moved to the death health state. Whereas, in the semi-
Markov MSM model all patients have reached this health state by ~10-years. 
Figure 2. Treatment benefit discontinuation scenarios in the PartSA
Abbreviations: PartSA, partitioned survival analysis
Overall survival extrapolations: up to 3-years Overall survival extrapolations: up to 15-years
